Status:
NOT_YET_RECRUITING
Human Umbilical Cord Blood Infusion in Patients with Acute Ischemic Stroke (AIS)
Lead Sponsor:
StemCyte, Inc.
Collaborating Sponsors:
StemCyte Taiwan Co., Ltd.
Conditions:
Acute Ischemic Stroke
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
A Phase II, Randomized, Double-blind, Parallel, Placebo-controlled Study to Assess the Safety and Efficacy of Human Umbilical Cord Blood Infusion in Patients with Acute Ischemic Stroke
Detailed Description
This is a phase II study to evaluate the safety and efficacy in hUCB treatment on the patients with acute ischemic stroke (AIS).
Eligibility Criteria
Inclusion
- Male or female subject ≥18 and ≤80 years of age.
- Subject with a confirmed diagnosis of AIS and hemiplegia
Exclusion
- Subject with known immune disease, immunodeficiency, or receives immunosuppressive therapy/immunomodulators within 4 weeks or 5 half-lives prior to screening, whichever is longer.
Key Trial Info
Start Date :
September 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2028
Estimated Enrollment :
39 Patients enrolled
Trial Details
Trial ID
NCT06040476
Start Date
September 1 2025
End Date
August 1 2028
Last Update
February 27 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.